Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$774K Buy
11,492
+2,313
+25% +$154K 0.03% 482
2026
Q1
$576K Buy
9,179
+3,091
+51% +$215K 0.03% 521
2025
Q4
$404K Sell
6,088
-955
-14% -$61.7K 0.02% 614
2025
Q3
$474K Buy
7,043
+169
+2% +$13.4K 0.03% 528
2025
Q2
$600K Sell
6,874
-444
-6% -$34.8K 0.04% 417
2025
Q1
$500K Sell
7,318
-940
-11% -$76.7K 0.04% 418
2024
Q4
$642K Buy
8,258
+2,665
+48% +$197K 0.05% 301
2024
Q3
$375K Buy
5,593
+2,293
+69% +$188K 0.04% 398
2024
Q2
$374K Buy
3,300
+248
+8% +$31.4K 0.05% 335
2024
Q1
$423K Buy
3,052
+374
+14% +$47K 0.09% 217
2023
Q4
$325K Buy
+2,678
New +$274K 0.09% 206

Other funds holding DXCM

GAMMA Investing's DXCM Position: Q2 2026 in Review

GAMMA Investing increased its DexCom (DXCM) stake by 25% in Q2 2026, buying an estimated $154K and bringing the position to 11,492 shares worth $774K. The position accounts for 0.03% of the portfolio, ranked #482.

GAMMA Investing first reported a position in DXCM in Q4 2023 and has held it in 11 quarters since. 136 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • GAMMA Investing held 11,492 shares of DexCom worth $774K as of Q2 2026.
  • GAMMA Investing bought 2,313 DexCom shares in Q2 2026, an estimated $154K.
  • DexCom made up 0.03% of GAMMA Investing's portfolio in Q2 2026, its #482 holding.
  • GAMMA Investing first reported a position in DexCom in Q4 2023 and has held it in 11 quarters since.
  • 136 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.